Volume | 1,725,749 |
|
|||||
News | - | ||||||
Day High | 10.59 | Low High |
|||||
Day Low | 10.32 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Amicus Therapeutics Inc | FOLD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
10.56 | 10.32 | 10.59 | 10.33 | 10.55 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
12,930 | 1,725,749 | $ 10.42 | $ 17,974,200 | - | 9.70 - 14.57 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:20:00 | formt | 270 | $ 10.33 | USD |
Amicus Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.05B | 295.38M | - | 399.36M | -151.58M | -0.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Amicus Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FOLD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.33 | 11.41 | 10.32 | 10.69 | 2,501,177 | -1.00 | -8.83% |
1 Month | 12.08 | 12.24 | 10.32 | 11.33 | 2,385,020 | -1.75 | -14.49% |
3 Months | 12.73 | 14.03 | 10.32 | 12.39 | 3,057,128 | -2.40 | -18.85% |
6 Months | 10.63 | 14.57 | 9.70 | 12.19 | 3,012,928 | -0.30 | -2.82% |
1 Year | 11.87 | 14.57 | 9.70 | 12.26 | 2,751,815 | -1.54 | -12.97% |
3 Years | 9.90 | 14.57 | 5.91 | 10.93 | 2,695,060 | 0.43 | 4.34% |
5 Years | 12.84 | 25.39 | 5.91 | 11.60 | 2,732,590 | -2.51 | -19.55% |
Amicus Therapeutics Description
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. |